Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 261Gynecologic 6Tumor-Agnostic 4Thoracic 4Other solid neoplasm 4Breast 3Dermatologic 2NET 1Head & Neck 1Genitourinary 1Endocrine 1CNS 1

Conditions

Ovarian Neoplasms 2Colorectal Neoplasms 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Folfox protocol × Dermatologic × Clear all
NCT00959647 2026-05-08

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Genentech, Inc.

Phase 2 Completed
19 enrolled 10 charts
DermatologicGastrointestinalGynecologic

Carcinoma, Basal Cell, Ovarian Neoplasms, Colorectal Neoplasms

NCT02009449 2024-11-15

IVY

Eli Lilly and Company

Phase 1 Completed
353 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡